A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-alpha and ribavirin therapy

作者：Murata Masayuki^*; Furusyo Norihiro; Ogawa Eiichi; Mitsumoto Fujiko; Hiramine Satoshi; Ikezaki Hiroaki; Takayama Koji; Shimizu Motohiro; Toyoda Kazuhiro; Kainuma Mosaburo; Hayashi Jun

来源：Journal of Infection and Chemotherapy, 2014, 20(5-6): 320-324.

DOI：10.1016/j.jiac.2013.11.006

• Hepatitis C virus
• Human immunodeficiency virus
• Hemophilia
• Antiretroviral therapy
• Telaprevir
• Pegylated interferon alpha

In Japan, the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection of some patients with hemophilia was caused by the transfusion of imported blood products, such as unheated coagulation factor. With the development of antiretroviral therapy (ART) for HIV, chronic HCV infection has become a major cause of liver disease and mortality for hemophiliac patients coinfected with HCV/HIV. Data is limited regarding the efficacy and safety of antiviral therapy with the HCV protease inhibitor telaprevir (TVR) in combination with pegylated interferon-alpha (PegIFN-alpha) and ribavirin (RBV) for hemophilia patients coinfected with HCV/HIV. We report a case of a Japanese patient with hemophilia and HCV/HIV coinfection who had partial response to prior to PegIFN-alpha and RBV therapy. This is the first published report of 24-week TVR-based triple therapy for a hemophilia patient coinfected with HCV/HIV. The patient had HCV genotype la infection with a high viral load. His single-nucleotide polymorphism of the interleukin 28B (rs8099917) gene was the IT major allele. He presented with undetectable HIV RNA and a high CD4(+) T cell counts by taking ART including tenofovir, emtricitabine and raltegravir. He was again treated for HCV with TVR plus PegIFN-alpha 2b and RBV for the first 12 weeks, followed by the continuation of PegIFN-alpha 2b and RBV for 12 additional weeks while continuing ART. He had rapid virological response and achieved sustained virological response with the 24-week treatment. No serious adverse events such as skin rash, severe anemia or exacerbated bleeding tendency were observed, only a mild headache. No dose adjustment was necessary when tenofovir and raltegravir were used in combined with TVR, and no HIV breakthrough was observed. TVR-based triple therapy with ART could can an effective treatment for hemophilia patients coinfected with HCV (genotype 1)/HIV regardless of prior response. TVR can be used in combination with tenofovir, emtricitabine and raltegravir for patients with hemophilia. Furthermore, patients with undetectable HCV RNA at week 4 could be successfully treated with a 24-week regimen.

• 出版日期2014-6